• 1
    Bonow RO, Lipson LC, Sheehan FH, et al., Lack of effect of aspirin on myocardial infarct size in the dog. Am J Cardiol 1981;47:258264.
  • 2
    Brezinski ME, Yanagisawa A, Lefer AM. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia. J Cardiovasc Pharmacol 1987;9:6571.
  • 3
    Brothers TE, Robison JG, Elliot BM, Boggs JM, Halushka PV. Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. Cardiovasc Surg 1997;5:9298.
  • 4
    DelliPizzi A, Nasjletti A. Involvement of nitric oxide and potassium channels in the reduction of basal tone produced by blockade of thromboxane A2/prostaglandin H2 receptors in aortic rings of hypertensive rats. Clin Exp Hypertens 1998;20:903916.
  • 5
    DelliPizzi A, Pucci ML, Mosny AY, Deseyn K, Nasjletti A. Contribution of constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats with aortic coarctation-induced hypertension: relationship to nitric oxide. J Pharmacol Exp Ther 1997;283:7581.
  • 6
    Dockens RC, Santone KS, Mitroka JG, et al. Disposition of radiolabeled ifetroban in rats, dogs, monkeys and humans. Drug Metab Dispos 2000;28:973980.
  • 7
    Fabi F, Argiolas L, Ruvolo G, del Basso P. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane. Br J Pharmacol 1998;124:101110.
  • 8
    Gao H, Peng B, Welch WJ, Wilcox CS. Central thromboxane receptors: mRNA expression and mediation of pressor responses. Am J Physiol 1997;272:R1493R1500.
  • 9
    Gao H, Welch WJ, DiBona GF, Wilcox CS. Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats. Am J Physiol 1997;273:H734H739.
  • 10
    Gomoll AW, Grover GJ, Ogletree ML. Myocardial salvage efficacy of the thromboxane receptor antagonist ifetroban in ferrets and dogs. J Cardiovasc Pharmacol 1994;24:960968.
  • 11
    Gomoll AW, Ogletree ML. Failure of aspirin to interfere with the cardioprotective effects of ifetroban. Eur J Pharmacol 1994;271:471479.
  • 12
    Gomoll AW, Schumacher WA, Ogletree ML. Dose-related cardioprotection by ifetroban in relation to inhibition of ex vivo platelet function. Pharmacology 1995;50:92110.
  • 13
    Grover GJ, Schumacher WA. Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve. J Pharmacol Exp Ther 1989;248:484491.
  • 14
    Grover GJ, Schumacher WA. The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia. Basic Res Cardiol 1989;84:103110.
  • 15
    Grover GJ, Schumacher WA, Ogletree ML. Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs. J Cardiovasc Pharmacol 1994;24:493499.
  • 16
    Grover GJ, Schumacher WA, Simon M, Parham C. The effect of the thromboxane A2/prostaglandin endo-peroxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 1988;12:701709.
  • 17
    Grover GJ, Sleph PG, Weiss HR. Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog. J Pharmacol Exp Ther 1990;253:10971102.
  • 18
    Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 1975;71:34004304.
  • 19
    Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:29942998.
  • 20
    Hammett J, Delaney C, Uderman H, et al. Single dose ifetroban-aspirin interaction in healthy male volunteers. Clin Pharmacol Ther 1995;57:141.
  • 21
    Hayakawa H, Raij L. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. J Hypertens 1999;17:611619.
  • 22
    Hoeft A, Korb H, Bock J, Wolpers HG, Wober W, Hellige G. Preservation of myocardium in transient ischemia by the thromboxane synthetase inhibitor UK 38,485. Res Exp Med 1986;186:3546.
  • 23
    Hock CE, Brezinski ME, Lefer AM. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia. Eur J Pharmacol 1986;122:213219.
  • 24
    Jemal M, Patel A, Teitz DS. Direct injection for high sample throughput capillary gas chromatographic-mass spectrometric bioanalysis. J Chromatogr B Biomed Appl 1995;666:251257.
  • 25
    Jimenez R, Andriambeloson E, Duarte J, et al. Involvement of thromboxane A2 in the endothelium-dependent contractions induced by myricetin in rat isolated aorta. Br J Pharmacol 1999;127:15391544.
  • 26
    Johnson RA, Belmonte A, Fan NY-T, Lavesa M, Nasjletti A, Stier CT, Jr. Effect of ifetroban, a thromboxane A2 receptor antagonist, in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1996;18:171188.
  • 27
    Kanagasabay R. Ifetroban sodium. Curr Opin Cardiovasc Pulm Renal Invest Drugs 1999;1:125130.
  • 28
    Katz SD, Radin M, Graves T, Hauck C, Block A, LeJemtel TH. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol 1999;34:170176.
  • 29
    Khan S, Teitz DS, Jemal M. Kinetic analysis by HPLC — Electrospray mass spectrometry of the pH-dependent acyl migration and solvolysis as the decomposition pathways of ifetroban 1-O-acyl glucuronide. Anal Chem 1998;70:16221628.
  • 30
    Koslo RJ, Farina V, Ogletree ML, Aberg G. Gastroprotective effect of BMS 180,291: a new thromboxane receptor antagonist. Gastroenterology 1992;102:A102.
  • 31
    Kulatilake N, Gonzalez-Lavin L, Grover GJ. Thromboxane A2 receptor blockade improves contractile function following cardiopulmonary bypass in dogs and pigs. J Surg Res 1991;51:336340.
  • 32
    Lewy RI, Wiener L, Walinsky P, Lefer AM, Silver MJ, Smith JB. Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation 1980;61:11651171.
  • 33
    Liao W, Delaney C, Uderman H, Jemal M, Ford N. The single-dose pharmacokinetics and tolerance of BMS 180291, a new thromboxane A2 receptor antagonist, in healthy male volunteers. Clin Pharmacol Ther 1994;55:168.
  • 34
    Lyon RT, Veith FJ, Bolton L, Machado F. Clinical benchmark for healing of chronic venous ulcers. Am J Surg 1998;176:172175.
  • 35
    Mayhan WG Role of prostaglandin H2-thromboxane A2 in responses of cerebral arterioles during chronic hypertension. Am J Physiol 1992;262:H539H543.
  • 36
    Michael LH, Hunt JR, Lewis RM, Entman ML. Myocardial ischemia: Platelet and thromboxane concentrations in cardiac lymph and the effects of ibuprofen and prostacyclin. Circ Res 1986;59:4955.
  • 37
    Misra RN, Brown BR, Sher PM, et al. Interphenylene 7-oxabicyclo[2.2.1]-heptane oxazoles. Highly potent, selective, and long-acting thromboxane A2 receptor antagonists. J Med Chem 1993;36:14011417.
  • 38
    Misra RN, Brown BR, Sher PM, et al. Interphenylene 7-oxabicycloheptane TxA2antagonists-BMS 180,291: anew clinical candidate. Abs Pap Am Chem Soc Med 1991;160:2530.
  • 39
    Misra RN, Brown BR, Sher PM, et al. Thromboxane receptor antagonist BMS-180291: a new pre-clinical lead. Bioorg Med Chem Lett 1992;2:7376.
  • 40
    Misra RN, White RE, Ogletree ML. Ifetroban sodium. Drugs Future 1994;19:107110.
  • 41
    Mohler ER, Franklin MT, Adam LP. Intracellular signaling by 8-epi-prostaglandin F2α is mediated by thromboxane A2/prostaglandin endoperoxide receptors in porcine carotid arteries. Biochem Biophys Res Commun 1996;225:915923.
  • 42
    Mueller RH. A practical synthesis of ifetroban sodium. In: GadamasettiKG, ed. Process chemistry in the pharmaceutical industry. New Brunswick : Marcel Dekker, 1999;3755.
  • 43
    Mueller RH, Wang S, Pansegrau PD, et al. Diastereoselective reaction of a grignard reagent with chiral imides: A practical preparation of a key intermediate in the synthesis of ifetroban sodium. Org Proc Res Devel 1997;1:1419.
  • 44
    Nanji AA, Khwaja S, Rahemtulla A, Miao L, Zhoa S, Tahan SR. Thromboxane inhibitors attenuate pathological changes in alcoholic liver disease in the rat. Gastroenterology 1997;112:200207.
  • 45
    Ogletree ML, Harris DN, Schumacher WA, Hall SE, Brown BR, Misra RN. BMS 180,291: Profile of a potent, orally active thromboxane A2/prostaglandin endoperoxide (TP) receptor antagonist. Circulation 1991;84:II79.
  • 46
    Ogletree ML, Harris DN, Schumacher WA, Webb ML, Misra RN. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther 1993;264:570578.
  • 47
    Ogletree ML. Coronary contraction induced by 8-epi PGF2α is independent of PGF2α receptors and is mediated by thromboxane receptors. Circulation 1992;86:I–298.
  • 48
    Phillipson DW, Tymiak AA, Tuttle JG, et al. Isolation and identification of lysophosphatidylcholines as endogenous modulators of thromboxane receptors. J Lipid Mediators 1993;7:155167.
  • 49
    Quinn JV, Slotman GJ. Platelet-activating factor and arachidonic acid metabolites mediate tumor necrosis factor and eicosanoid kinetics and cardiopulmonary dysfunction during bacteremic shock. Crit Care Med 1999;27:24852494.
  • 50
    Reddy DS. Newer antithrombotic drugs. East Pharm 1997;40:2731.
  • 51
    Remuzzi G, Noris M, Benigni A, Imberti O, Sayegh MH, Perico N. Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides. J Exp Med 1994;180:19671972.
  • 52
    Rocha, R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451458.
  • 53
    Schumacher WA, Grover GJ. The thromboxane receptor antagonist SQ 30,741 reduces myocardial infarct size in monkeys when given during reperfusion at a threshold dose for improving reflow during thrombolysis. J Am Coll Cardiol 1990;15:883889.
  • 54
    Schumacher WA, Heran CL, Steinbacher TE, Youssef S, Ogletree ML. Superior activity of a thromboxane receptor antagonist compared to aspirin in rat models of arterial and venous thrombosis. J Cardiovasc Pharmacol 1993;22:526533.
  • 55
    Schumacher WA, Steinbacher TE, Heran CL, Megill JR, Durham SK. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemostas 1993;69:509514.
  • 56
    Schumacher WA, Steinbacher TE, Megill JR, Durham SK. A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin. J Pharmacol Toxicol Meth 1996;35:310.
  • 57
    Schumacher WA, Steinbacher TE, Youssef S, Ogletree ML. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins 1992;44:389397.
  • 58
    Shoenfeld Y, Blank M. Effect of long-acting thromboxane receptor antagonist (BMS-180,291) on experimental antiphosphoslipid-syndrome. Lupus 1994;3:397400.
  • 59
    Sibbald RG. Venous leg ulcers. Ostomy Wound Manage 1998;44:5268.
  • 60
    Sigmon DH, Beierwaltes WH. Endothelium-derived constricting factor in renovascular hypertension. Hypertension 1995;25:803808.
  • 61
    Spagnuolo PJ, Ellner JJ, Hassid A, Dunn MJ. Thromboxane A2 mediates augmented polymorphonuclear leukocyte adhesiveness. J Clin Invest 1980;66:406414.
  • 62
    Stier CT, Jr., Benter IF, Ahmad S, et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989;13:115121.
  • 63
    Stier CT, Jr., Benter IF, Levine S. Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats. Stroke 1988;19:11451150.
  • 64
    Stier CT, Jr., Spokas EG. The role of thromboxane A2 in hypertension. Cardiovasc Rev Rep 1988;9:3238.
  • 65
    Stratmann HG. Ifetroban. Curr Res Vasc Dis 1998;3:293298.
  • 66
    Swaminathan S, Singh AK, Li WS, et al. A chemoselective, acid mediated conversion of amide acetal to oxazole: The key step in the synthesis of cardiovascular drug, ifetroban sodium. Tetrahedron Lett 1998;39:47694772.
  • 67
    Swanson BN, Manning JA, Ogletree ML, et al. Effect of BMS-180291, a long-acting thromboxane A receptor antagonist, on platelet function in healthy men. Clin Pharm Therap 1994;55:202.
  • 68
    Tesfamariam B, Ogletree ML. Dissociation of endothelial cell dysfunction and blood pressure in SHR. Am J Physiol 1995;269:H189194.
  • 69
    Tesfamariam B. Selective impairment of endothelium-dependent relaxations by prostaglandin endoperoxide. J Hypertension 1994;12:4147.
  • 70
    The SALT Collaborative Group: Swedish aspirin low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:13451349.
  • 71
    Viehman GE, Ma X-L, Lefer AM. Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium. Meth Find Exp Clin Pharmacol 1990;12:651656.
  • 72
    Walker M, Hulme TA, Rippon MG, et al. In vitro model(s) for the percutaneous delivery of active tissue repair agents. J Pharm Sci 1997;86:13791384.
  • 73
    Warner, TD, Giuliano, F, Vojnovic, I, Bukasa, A, Mitchell, JA, Vane, JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999;96:75637568.
  • 74
    Webb ML, Liu ECK, Monshizadegan H, et al. Binding and function of a potent new thromboxane receptor antagonist, BMS 180,291, in human platelets. J Pharmacol Exp Ther 1993;264:13871394.
  • 75
    Wilcox CS, Cardozo J, Welch WJ. AT1 and TxA2/PGH2 receptors maintain hypertension throughout 2K, 1C Goldblatt hypertension in the rat. Am J Physiol 1996;271:R891R896.
  • 76
    Wilcox CS, Gao H, Verbalis JG, Welch WJ. Role of AVP in pressor responses during activation of central TxA/PGH2 receptors. Am J Physiol 1997;273:H1927H1932.
  • 77
    Young W, Mahboubi K, Haider A, Ferreri NR. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells. Circ Res 2000;86:906914.